Acasti Pharma Inc. (NASDAQ:ACST – Get Free Report) was the target of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 154,200 shares, a growth of 19.6% from the September 30th total of 128,900 shares. Based on an average daily volume of 27,200 shares, the days-to-cover ratio is currently 5.7 days. Currently, 2.5% of the company’s shares are sold short.
Analyst Upgrades and Downgrades
ACST has been the topic of several research reports. Craig Hallum raised their price target on shares of Acasti Pharma from $6.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, September 26th. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Acasti Pharma in a research note on Thursday, September 26th.
Get Our Latest Research Report on ACST
Institutional Inflows and Outflows
Acasti Pharma Price Performance
Shares of ACST opened at $3.37 on Monday. Acasti Pharma has a 12 month low of $1.98 and a 12 month high of $3.60. The stock’s 50-day moving average is $2.84 and its two-hundred day moving average is $2.87. The stock has a market cap of $31.67 million, a PE ratio of -2.34 and a beta of 1.52.
Acasti Pharma (NASDAQ:ACST – Get Free Report) last announced its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.04. On average, research analysts anticipate that Acasti Pharma will post -1.11 earnings per share for the current year.
Acasti Pharma Company Profile
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Further Reading
- Five stocks we like better than Acasti Pharma
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Tickers Leading a Meme Stock Revival
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.